DK3284463T3 - Nitroxyldonorer med forbedret terapeutisk indeks - Google Patents

Nitroxyldonorer med forbedret terapeutisk indeks Download PDF

Info

Publication number
DK3284463T3
DK3284463T3 DK17195759T DK17195759T DK3284463T3 DK 3284463 T3 DK3284463 T3 DK 3284463T3 DK 17195759 T DK17195759 T DK 17195759T DK 17195759 T DK17195759 T DK 17195759T DK 3284463 T3 DK3284463 T3 DK 3284463T3
Authority
DK
Denmark
Prior art keywords
therapeutic index
improved therapeutic
nitroxyl donors
nitroxyl
donors
Prior art date
Application number
DK17195759T
Other languages
Danish (da)
English (en)
Inventor
Vincent Jacob Kalish
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John P Toscano
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3284463T3 publication Critical patent/DK3284463T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17195759T 2013-01-18 2014-01-17 Nitroxyldonorer med forbedret terapeutisk indeks DK3284463T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
EP14703009.2A EP2945620B1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index

Publications (1)

Publication Number Publication Date
DK3284463T3 true DK3284463T3 (da) 2019-10-28

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17195759T DK3284463T3 (da) 2013-01-18 2014-01-17 Nitroxyldonorer med forbedret terapeutisk indeks
DK14703010.0T DK2945621T3 (en) 2013-01-18 2014-01-17 PHARMACEUTICAL COMPOSITIONS CONTAINING NITROXYL DONORS
DK14703009.2T DK2945620T3 (en) 2013-01-18 2014-01-17 NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK14703010.0T DK2945621T3 (en) 2013-01-18 2014-01-17 PHARMACEUTICAL COMPOSITIONS CONTAINING NITROXYL DONORS
DK14703009.2T DK2945620T3 (en) 2013-01-18 2014-01-17 NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX

Country Status (29)

Country Link
US (13) US8987326B2 (enExample)
EP (5) EP3284463B1 (enExample)
JP (5) JP6449171B2 (enExample)
KR (2) KR102277165B1 (enExample)
CN (4) CN110179777B (enExample)
AU (5) AU2014207408C1 (enExample)
BR (2) BR112015017251B1 (enExample)
CA (2) CA2898443C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK3284463T3 (enExample)
ES (4) ES2705240T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20182144T1 (enExample)
HU (3) HUE046722T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT3284463T (enExample)
MX (2) MX363843B (enExample)
NZ (4) NZ709985A (enExample)
PL (3) PL3284463T3 (enExample)
PT (3) PT2945621T (enExample)
RS (3) RS59434B1 (enExample)
RU (3) RU2676277C2 (enExample)
SG (6) SG10201913286PA (enExample)
SI (3) SI3284463T1 (enExample)
SM (3) SMT201900027T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI686193B (enExample)
WO (2) WO2014113696A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595770A (en) 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
LT3284463T (lt) 2013-01-18 2019-11-11 Cardioxyl Pharmaceuticals Inc Nitroksilo donorai, pasižymintys geresniais terapiniais rodikliais
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3348548A4 (en) 2015-09-07 2019-04-03 Zhejiang Huahai Pharmaceutical Co., Ltd STAIN OXIDE-RELIEFING PRODRUG MOLECULE
EP3365325A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
WO2017070081A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3490975B1 (en) 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
US11083704B2 (en) * 2017-01-03 2021-08-10 Bristol-Myers Squibb Company Method of administering nitroxyl donating compounds
EP3612175B1 (en) * 2017-04-18 2025-09-10 Genfit Combination of elafibranor with an anti-nash, anti-fibrotic or anti-cholestatic agent
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
AU679834B2 (en) * 1994-01-19 1997-07-10 Byk Nederland Bv Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
AU741180B2 (en) 1997-10-24 2001-11-22 Shionogi & Co., Ltd. Antirheumatic
DK0930302T3 (da) * 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
ATE292961T1 (de) 1998-07-28 2005-04-15 Tanabe Seiyaku Co Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
BR0116063A (pt) * 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2007522135A (ja) 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
NZ595770A (en) * 2006-03-17 2013-04-26 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
NZ584036A (en) * 2007-09-26 2012-06-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2601192T3 (es) 2008-05-07 2017-02-14 Cardioxyl Pharmaceuticals Inc. Nuevos compuestos nitrosos como donadores de nitroxilo y métodos de uso de los mismos
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
US20110144067A1 (en) * 2009-12-07 2011-06-16 Toscano John P N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
CN102753519B (zh) * 2009-12-07 2015-08-05 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
LT3284463T (lt) 2013-01-18 2019-11-11 Cardioxyl Pharmaceuticals Inc Nitroksilo donorai, pasižymintys geresniais terapiniais rodikliais
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
ZA201505090B (en) 2016-10-26
HK1216857A1 (en) 2016-12-09
ZA201604798B (en) 2018-01-31
KR20150108879A (ko) 2015-09-30
CN105142627B (zh) 2019-06-21
CN110179777A (zh) 2019-08-30
HK1216858A1 (en) 2016-12-09
DK2945621T3 (en) 2019-02-11
US20190133990A1 (en) 2019-05-09
CY1121480T1 (el) 2020-05-29
JP2017125015A (ja) 2017-07-20
US20170151210A1 (en) 2017-06-01
CA2898443C (en) 2022-05-31
WO2014113700A9 (en) 2014-10-09
DK2945620T3 (en) 2018-02-05
RS59434B1 (sr) 2019-11-29
BR112015017251A2 (pt) 2017-07-11
SG10201913441RA (en) 2020-03-30
HUE041861T2 (hu) 2019-06-28
US20200163929A1 (en) 2020-05-28
HUE046722T2 (hu) 2020-03-30
LT2945621T (lt) 2019-01-10
BR112015017241A2 (pt) 2017-07-11
JP6533159B2 (ja) 2019-06-19
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
PT3284463T (pt) 2019-10-30
CN105142627A (zh) 2015-12-09
LT2945620T (lt) 2018-02-12
US9968584B2 (en) 2018-05-15
BR112015017241B1 (pt) 2021-10-26
TWI686193B (zh) 2020-03-01
TWI712409B (zh) 2020-12-11
US11786501B2 (en) 2023-10-17
AU2014207408B2 (en) 2018-03-01
ES2705240T3 (es) 2019-03-22
PT2945620T (pt) 2018-02-21
US20150175566A1 (en) 2015-06-25
CN108610312A (zh) 2018-10-02
CN105073105A (zh) 2015-11-18
US20190224159A1 (en) 2019-07-25
MX363843B (es) 2019-04-05
RU2018143994A (ru) 2019-01-16
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
IL239906B (en) 2018-05-31
BR112015017241A8 (pt) 2019-10-29
PL2945621T3 (pl) 2019-05-31
AU2018241168A1 (en) 2018-11-01
CA2898443A1 (en) 2014-07-24
PL2945620T3 (pl) 2018-03-30
JP6311038B2 (ja) 2018-04-11
IL239952A0 (en) 2015-08-31
WO2014113700A1 (en) 2014-07-24
US10245249B2 (en) 2019-04-02
HRP20191919T8 (hr) 2021-10-01
SG11201505567RA (en) 2015-09-29
HUE036589T2 (hu) 2018-07-30
CY1122177T1 (el) 2020-11-25
IL259233B (en) 2019-10-31
AU2014207404A1 (en) 2015-08-13
AU2014207404B2 (en) 2017-10-19
MX373176B (es) 2020-04-22
KR102177899B1 (ko) 2020-11-12
NZ709986A (en) 2020-01-31
RU2015134583A (ru) 2017-02-22
LT3284463T (lt) 2019-11-11
SG10201913286PA (en) 2020-02-27
KR102277165B1 (ko) 2021-07-14
CN110179777B (zh) 2022-07-15
SMT201800088T1 (it) 2018-03-08
RS58174B1 (sr) 2019-03-29
PT2945621T (pt) 2019-01-21
US20140206769A1 (en) 2014-07-24
EP3427728B1 (en) 2021-07-07
KR20150107853A (ko) 2015-09-23
IL258882A (en) 2018-06-28
NZ748769A (en) 2020-05-29
ES2882279T3 (es) 2021-12-01
NZ748771A (en) 2019-12-20
TR201802211T4 (tr) 2018-03-21
IL239906A0 (en) 2015-08-31
US8987326B2 (en) 2015-03-24
AU2017200147B2 (en) 2018-07-05
HRP20191919T1 (hr) 2020-01-10
CN105073105B (zh) 2018-02-27
AU2018241168B2 (en) 2020-04-02
BR112015017251B1 (pt) 2021-10-26
RU2676277C2 (ru) 2018-12-27
AU2014207408A1 (en) 2015-08-13
US10792273B2 (en) 2020-10-06
AU2018203240A1 (en) 2018-05-31
AU2018203240B2 (en) 2019-12-12
US10517847B2 (en) 2019-12-31
JP6801045B2 (ja) 2020-12-16
JP6656345B2 (ja) 2020-03-04
TW201442702A (zh) 2014-11-16
US11273143B2 (en) 2022-03-15
IL259233A (en) 2018-07-31
US10213408B2 (en) 2019-02-26
NZ709985A (en) 2020-05-29
SI3284463T1 (sl) 2019-12-31
US9156804B2 (en) 2015-10-13
SI2945621T1 (sl) 2019-01-31
JP2019172682A (ja) 2019-10-10
JP2016505044A (ja) 2016-02-18
SG10201802862WA (en) 2018-05-30
CA2898445C (en) 2022-05-03
EP3284463B1 (en) 2019-07-24
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
JP6449171B2 (ja) 2019-01-09
BR112015017251A8 (pt) 2019-10-29
MX2015009276A (es) 2015-10-30
US20220193026A1 (en) 2022-06-23
ES2751922T3 (es) 2020-04-02
US12186301B2 (en) 2025-01-07
EP3284463A1 (en) 2018-02-21
TW201934120A (zh) 2019-09-01
CA2898445A1 (en) 2014-07-24
EP2945620B1 (en) 2017-11-22
SG10201802855TA (en) 2018-05-30
AU2014207408A8 (en) 2015-08-27
HRP20180121T1 (hr) 2018-02-23
US20210015784A1 (en) 2021-01-21
SMT201900575T1 (it) 2019-11-13
RU2684916C2 (ru) 2019-04-16
US10548872B2 (en) 2020-02-04
TWI619491B (zh) 2018-04-01
HRP20182144T1 (hr) 2019-03-08
WO2014113696A1 (en) 2014-07-24
PL3284463T3 (pl) 2019-12-31
EP3567031A1 (en) 2019-11-13
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
EP3427728A1 (en) 2019-01-16
MX2015009269A (es) 2015-10-30
JP2019089764A (ja) 2019-06-13
SI2945620T1 (en) 2018-01-31
EP2945620A1 (en) 2015-11-25
TW201446242A (zh) 2014-12-16
US9586896B2 (en) 2017-03-07
AU2014207408C1 (en) 2018-09-06
ES2659969T3 (es) 2018-03-20
JP2016510326A (ja) 2016-04-07
US20180235927A1 (en) 2018-08-23
US20240066002A1 (en) 2024-02-29
SMT201900027T1 (it) 2019-02-28
HK1251170B (en) 2020-04-09
IL239952B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
HRP20191919T8 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
DK4056212T3 (da) Autoinjektor
DK3778897T3 (da) Immunonkolytiske terapier
DK2978844T3 (da) Modificerede tgf-beta2-oligonukleotider
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
EP2815053A4 (en) PORTAL
PT2961752T (pt) Imidazopiridazinas substituídas
BR112016011147A2 (pt) autoinjetor
EP2963075A4 (en) OBJECT MOLDED IN POLYCARBONATE
EP2973370A4 (en) PREDICTIVE MEDICAMENT SAFETY
DE202014011220U8 (de) Polycarbonatharzzusammensetzung
DK3080385T3 (da) Forbedret lukkeapparat
FR3003469B1 (fr) Autoinjecteur
FR3003470B1 (fr) Autoinjecteur
DE112014002244A5 (de) Infusionslösung
BR302014000168S1 (pt) Configuração aplicada em seringa
UA28329S (uk) Шприц
PT11257U (pt) Seringa
UA27828S (uk) Спринцівка
TH1401007760A (th) กระบอกฉีดยา
DK2754851T3 (da) Forbedret borerør
UA30187S (uk) Ампула
FI10093U1 (fi) Jalusta
ES1080729Y (es) Balaustre mejorado
TH1501003669A (th) สารผสมของพอลิโอเลฟิน